Reduced quality of life associated adverse events in intermediate hepatocellular carcinoma patients treated with PRECISION TACE with drug eluting beads: Results from the PRECISION V randomized trial : B-241
Details
Serval ID
serval:BIB_0C3A2F5996A8
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
Reduced quality of life associated adverse events in intermediate hepatocellular carcinoma patients treated with PRECISION TACE with drug eluting beads: Results from the PRECISION V randomized trial : B-241
Title of the conference
ECR 2010, 22nd European Congress of Radiology
Address
Vienna, Austria, March 4-8, 2010
ISBN
1869-4101
Publication state
Published
Issued date
2010
Volume
1
Series
Insights into Imaging
Pages
S183
Language
english
Abstract
Purpose: To evaluate the extent of quality of life (QoL) associated adverse events
(AEs) following PRECISION TACE with DC Bead compared with conventional
transarterial chemoembolisation (cTACE).
Methods and Materials: 201 intermediate HCC patients were treated with DC
Bead (PRECISION TACE) or conventional TACE (cTACE) with doxorubicin in
the PRECISION V clinical study. 93 patients were treated with DC Bead and 108
Patients with cTACE every 2 months and followed up for 6 months. AEs were classified
according to the South West Oncology Group criteria. QoL associated AEs
were defined as alopecia, constipation, nausea, vomiting, pyrexia, chills, asthenia,
fatigue, and headache.
Results: The biggest difference in QoL associated AEs was for alopecia: 2 patients
(2.2%) for DC-Bead versus 21 patients (19.4%) for cTACE. For other clinical
symptoms, constipation (n=10; 10.8% vs. n=13; 12%), vomiting (n=10; 10.8% vs.
n=14; 13.0%), pyrexia (n=16; 17.2% vs. n=26; 24.1%), chills (n=1; 1.1% vs. n=5;
4.6%), and headache (n=2; 2.2% vs. n=8; 7.4%) showed lower incidence in the
DC Bead group versus cTACE. Nausea, n= 15; 13.9% (n=15; 16.1%) and fatigue,
n=6; 5.6% (n=13; 14.0%) were lower for cTACE. Total dose of doxorubicin was on
average 35% higher in the DC Bead group.
Conclusion: Although patients in the DC Bead group received a higher doxorubicin
dose, less QoL associated AEs were reported for this group. Alopecia, the most obvious
outward sign of toxicity, was only reported in a tenth of DC Bead patients. Thus,
PRECISION TACE with DC Bead improves quality of life associated adverse events.
(AEs) following PRECISION TACE with DC Bead compared with conventional
transarterial chemoembolisation (cTACE).
Methods and Materials: 201 intermediate HCC patients were treated with DC
Bead (PRECISION TACE) or conventional TACE (cTACE) with doxorubicin in
the PRECISION V clinical study. 93 patients were treated with DC Bead and 108
Patients with cTACE every 2 months and followed up for 6 months. AEs were classified
according to the South West Oncology Group criteria. QoL associated AEs
were defined as alopecia, constipation, nausea, vomiting, pyrexia, chills, asthenia,
fatigue, and headache.
Results: The biggest difference in QoL associated AEs was for alopecia: 2 patients
(2.2%) for DC-Bead versus 21 patients (19.4%) for cTACE. For other clinical
symptoms, constipation (n=10; 10.8% vs. n=13; 12%), vomiting (n=10; 10.8% vs.
n=14; 13.0%), pyrexia (n=16; 17.2% vs. n=26; 24.1%), chills (n=1; 1.1% vs. n=5;
4.6%), and headache (n=2; 2.2% vs. n=8; 7.4%) showed lower incidence in the
DC Bead group versus cTACE. Nausea, n= 15; 13.9% (n=15; 16.1%) and fatigue,
n=6; 5.6% (n=13; 14.0%) were lower for cTACE. Total dose of doxorubicin was on
average 35% higher in the DC Bead group.
Conclusion: Although patients in the DC Bead group received a higher doxorubicin
dose, less QoL associated AEs were reported for this group. Alopecia, the most obvious
outward sign of toxicity, was only reported in a tenth of DC Bead patients. Thus,
PRECISION TACE with DC Bead improves quality of life associated adverse events.
Publisher's website
Create date
28/07/2010 7:14
Last modification date
20/08/2019 12:33
Usage data
